Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Protagonist Therapeutics Inc
PTGX | US
100.00
USD-2.62
-2.55%
PTGX | US
Loading StockChartView...
About Protagonist Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
100.00
Open
103.59
High
105.94
Low
98.91
Protagonist Therapeutics Inc. a biopharmaceutical company develops peptide-based drugs for hematology and blood disorders and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300) an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis iron overload and other blood disorders; and JNJ-2113 an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943 an orally delivered gut-restricted alpha 4 beta 7 specific integrin antagonist which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech Inc. Protagonist Therapeutics Inc. was incorporated in 2006 and is headquartered in Newark California.
View LessPTGX | US
Risk
45.8
Sharpe
2.25
Luna's Score
49/100
Recommendation
Hold
Luna says (PTGX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
50.8%1 month
45.8%3 months
41.4%6 months
37.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
17.27
Fwd. PE
42.02
Price to book
5.12
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
14.24
Ent. to rev.
6.95
PEG
-
Other Fundamentals
EBITDA
153.21M
MarketCap
5.89B
MarketCap(USD)
5.89B
Div. yield
-
Op. margin
-930.96
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
40.69
Short ratio
4.70
Short perc.
6.06
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
11.50
Range1M
12.44
Range3M
30.84
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.96
Price X volume
66.61M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 14.24 | 0.53 | Expensive |
| Ent. to Revenue | 6.95 | 3,967.00 | Cheaper |
| PE Ratio | 17.27 | 41.03 | Cheaper |
| Price to Book | 5.12 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 41.42 | 72.80 | Lower Risk |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 5.89B | 3.66B | Market Leader |
